The SeroNet Clinical and Translational Serology Task Force (CTTF) SARS-CoV-2 mucosal immunity methodological considerations and best practices workshop

References

• Kim C, Kim JD, Seo SU. Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2. J Microbiol. 2022;60(3):335–5. doi:10.1007/s12275-022-1608-z.
   PubMed Web of Science ®Google Scholar
• Wambani J, Okoth P. Scope of SARS-CoV-2 variants, mutations, and vaccine technologies. Egypt J Intern Med. 2022;34(1):34. doi:10.1186/s43162-022-00121-z.
   PubMedGoogle Scholar
• Lopez S. Clinical and translational serology highlights: SeroNews. 2021. https://frederick.cancer.gov/initiatives/serological-sciences-network/seronews/newsletter-issue-1.
   Google Scholar
• Havervall S, Marking U, Svensson J, Greilert-Norin N, Bacchus P, Nilsson P, Hober S, Gordon M, Blom K, Klingström J, et al. Anti-spike mucosal IgA protection against SARS-CoV-2 Omicron infection. N Engl J Med. 2022;387(14):1333–6. doi:10.1056/NEJMc2209651.
   PubMed Web of Science ®Google Scholar
• Marking U, Bladh O, Havervall S, Svensson J, Greilert-Norin N, Aguilera K, Kihlgren M, Salomonsson A-C, Månsson M, Gallini R, et al. 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection. Lancet Infect Dis. 2023;23(2):150–2. doi:10.1016/s1473-3099(22)00834-9.
   PubMed Web of Science ®Google Scholar
• Dunning J, Thwaites RS, Openshaw PJM. Seasonal and pandemic influenza: 100 years of progress, still much to learn. Mucosal Immunol. 2020;13(4):566–73. doi:10.1038/s41385-020-0287-5.
   PubMed Web of Science ®Google Scholar
• Habibi MS, Thwaites RS, Chang M, Jozwik A, Paras A, Kirsebom F, Varese A, Owen A, Cuthbertson L, James P, et al. Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection. Science. 2020;370(6513). doi:10.1126/science.aba9301.
   Web of Science ®Google Scholar
• Killingley B, Mann AJ, Kalinova M, Boyers A, Goonawardane N, Zhou J, Lindsell K, Hare SS, Brown J, Frise R, et al. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nat Med. 2022;28(5):1031–41. doi:10.1038/s41591-022-01780-9.
   PubMed Web of Science ®Google Scholar
• Liew F, Talwar S, Cross A, Willett BJ, Scott S, Logan N, Siggins MK, Swieboda D, Sidhu JK, Efstathiou C, et al. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBioMedicine. 2023;87:104402. doi:10.1016/j.ebiom.2022.104402.
   PubMed Web of Science ®Google Scholar
• Prabhakaran M, Narpala S, Andrews SF, O’Connell S, Lin CL, Coates EE, Flach B, Ledgerwood JE, McDermott AB. A sensitive method to quantify HIV-1 antibodies in mucosal samples. J Immunol Methods. 2021;491:112995. doi:10.1016/j.jim.2021.112995.
   PubMed Web of Science ®Google Scholar
• Astronomo RD, Lemos MP, Narpala SR, Czartoski J, Fleming LB, Seaton KE, Prabhakaran M, Huang Y, Lu Y, Westerberg K, et al. Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. J Clin Invest. 2021;131(16). doi:10.1172/jci146975.
   PubMed Web of Science ®Google Scholar
• Huang N, Pérez P, Kato T, Mikami Y, Okuda K, Gilmore RC, Conde CD, Gasmi B, Stein S, Beach M, et al. SARS-CoV-2 infection of the oral cavity and saliva. Nat Med. 2021;27(5):892–903. doi:10.1038/s41591-021-01296-8.
   PubMed Web of Science ®Google Scholar
• Bladh O, Marking U, Havervall S, Norin NG, Aguilera K, Hober S, Smed-Sörensen A, Gordon M, Blom K, Åberg M, et al. Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose. Lancet Microbe. 2023;4(7):e488. doi:10.1016/s2666-5247(23)00102-7.
   PubMedGoogle Scholar
• Ishizaka A, Koga M, Mizutani T, Uraki R, Yamayoshi S, Iwatsuki-Horimoto K, Yamamoto S, Imai M, Tsutsumi T, Suzuki Y, et al. Research article antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination. Virol J. 2023;20(1):146. doi:10.1186/s12985-023-02113-z.
   PubMed Web of Science ®Google Scholar
• Stolovich-Rain M, Kumari S, Friedman A, Kirillov S, Socol Y, Billan M, Pal RR, Das K, Golding P, Oiknine-Djian E, et al. Intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces neutralizing salivary IgA. Front Immunol. 2022;13:933347. doi:10.3389/fimmu.2022.933347.
   PubMed Web of Science ®Google Scholar
• WHO. WHO manual for the establishment of national and other secondary standards for antibodies against infectious agents focusing on SARS-CoV2. World Health Organization; 2022.
   Google Scholar
• WHO. Recommendations for the preparation, characterization and establishment of international and other biological reference standards (revised 2004). WHO Tech Rep series. 2006;932:73–130.
   Google Scholar
• Bentley E. Establishment of the 2nd WHO International Standard for anti-SARS-CoV-2 immunoglobulin and Reference Panel for antibodies to SARS-CoV-2 variants of concern. World Health Organization; 2022. https://www.who.int/publications/m/item/who-bs-2022.2427. WHO REFERENCE NUMBER: WHO/BS/2021.2427.
   Google Scholar
• Knezevic I, Mattiuzzo G, Page M, Minor P, Griffiths E, Nuebling M, Moorthy V. WHO International standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. Lancet Microbe. 2022;3(3):e235–e40. doi:10.1016/S2666-5247(21)00266-4.
   PubMedGoogle Scholar
• Nahass GR, Salomon-Shulman RE, Blacker G, Haider K, Brotherton R, Teague K, Yiu YY, Brewer RE, Galloway SD, Hansen P, et al. Intramuscular SARS-CoV-2 vaccines elicit varying degrees of plasma and salivary antibody responses as compared to natural infection. medRxiv. 2021. doi:10.1101/2021.08.22.21262168.
   Google Scholar
• Li C, Lam E, Perez-Shibayama C, Ward LA, Zhang J, Lee D, Nguyen A, Ahmed M, Brownlie E, Korneev KV, et al. Early-life programming of mesenteric lymph node stromal cell identity by the lymphotoxin pathway regulates adult mucosal immunity. Sci Immunol. 2019;4(42). doi:10.1126/sciimmunol.aax1027.
   Web of Science ®Google Scholar
• Sheikh-Mohamed S, Isho B, Chao GYC, Zuo M, Cohen C, Lustig Y, Nahass GR, Salomon-Shulman RE, Blacker G, Fazel-Zarandi M, et al. Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. Mucosal Immunol. 2022;15(5):1–0. doi:10.1038/s41385-022-00511-0.
   PubMedGoogle Scholar
• Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, Li Z, Chao G, Rojas OL, Bang YM, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020;5(52). doi:10.1126/sciimmunol.abe5511.
   PubMed Web of Science ®Google Scholar
• Qiu X, Xu S, Lu Y, Luo Z, Yan Y, Wang C, Ji J. Development of mRNA vaccines against respiratory syncytial virus (RSV). Cytokine Growth Factor Rev. 2022;68:37–53. doi:10.1016/j.cytogfr.2022.10.001.
   PubMed Web of Science ®Google Scholar